Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study

https://www.thelancet.com/coronavirus?dgcid=hubspot_email_conferencealerts_lancetcams23&utm_campaign=conferencealerts&utm_medium=email&_hsmi=283610531&_hsenc=p2ANqtz--_xoQonfXh4p_8Ax00Qxiox-m8Peduk1n4P9OA1pFtUHHJpNH3jZxQPmw1N6shV_qOPAta-xhSIp8J9kKIX6HiREosKg&utm_content=283610531&utm_source=hs_email